These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38240051)

  • 21. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
    Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
    Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploring the educational needs for severe immune-related adverse events of PD-1/PD-L1 inhibitors in advanced lung cancer: A single-center observational study.
    Aso S; Kawamura N; Yanagida H; Nakajima K; Ishikawa H; Omori S; Murakami H; Takahashi T; Naito T
    Asia Pac J Oncol Nurs; 2022 Aug; 9(8):100076. PubMed ID: 36065289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and validation of a risk-prediction model for immune-related adverse events in patients with non-small-cell lung cancer receiving PD-1/PD-L1 inhibitors.
    Qiu Q; Wu C; Tang W; Ji L; Dai G; Gao Y; Chen E; Jiang H; Xie X; Zhang J
    J Zhejiang Univ Sci B; 2023 Oct; 24(10):935-942. PubMed ID: 37752094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of Thyroid Dysfunction in PD-1 Blockade Is Stratified by the Pattern of TgAb and TPOAb Positivity at Baseline.
    Zhou X; Iwama S; Kobayashi T; Ando M; Arima H
    J Clin Endocrinol Metab; 2023 Sep; 108(10):e1056-e1062. PubMed ID: 37084392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1/PD-L1 Inhibitors in Cancer Patients: An Updated Systematic Review and Meta-Analysis.
    Tian Y; Li R; Liu Y; Li M; Song Y; Zheng Y; Gao A; Wen Q; Su G; Sun Y
    Front Oncol; 2021; 11():667650. PubMed ID: 34322382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 Blockade.
    Kobayashi T; Iwama S; Yamagami A; Yasuda Y; Okuji T; Ito M; Zhou X; Ando M; Onoue T; Miyata T; Sugiyama M; Hagiwara D; Suga H; Banno R; Hase T; Morise M; Ito T; Kikumori T; Inoue M; Ando Y; Masuda N; Kawashima H; Hashimoto N; Arima H
    J Clin Endocrinol Metab; 2022 Sep; 107(10):e4115-e4123. PubMed ID: 35918067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical characteristics and risk factors of programmed death-1 inhibitors associated with thyroid gland injury].
    Gong WW; Zhou FY; Guo QH
    Zhonghua Nei Ke Za Zhi; 2023 Feb; 62(2):176-181. PubMed ID: 36740408
    [No Abstract]   [Full Text] [Related]  

  • 28. Immunogenetic variations predict immune-related adverse events for PD-1/PD-L1 inhibitors.
    Xin Z; You L; Na F; Li J; Chen M; Song J; Bai L; Chen J; Zhou J; Ying B
    Eur J Cancer; 2023 May; 184():124-136. PubMed ID: 36917924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune-related adverse events associated with immune checkpoint inhibitors for advanced gastric and gastroesophageal junction cancer: A meta-analysis.
    Pei WG; Chen WZ; Wu YK; Tan SX; Jie ZG
    World J Gastrointest Oncol; 2023 Feb; 15(2):352-367. PubMed ID: 36908315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis.
    Wang PF; Chen Y; Song SY; Wang TJ; Ji WJ; Li SW; Liu N; Yan CX
    Front Pharmacol; 2017; 8():730. PubMed ID: 29093678
    [No Abstract]   [Full Text] [Related]  

  • 31. Thyroid-related adverse events induced by immune checkpoint inhibitors.
    Chera A; Stancu AL; Bucur O
    Front Endocrinol (Lausanne); 2022; 13():1010279. PubMed ID: 36204105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The safety of first and subsequent lines of PD-1/PD-L1 inhibitors monotherapy in non-small cell lung cancer patients: a meta-analysis.
    Yang Y; Pang P; Xie Z; Wang N; Liang H; Zhao L
    Transl Cancer Res; 2020 May; 9(5):3231-3241. PubMed ID: 35117689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.
    Wang M; Liang H; Wang W; Zhao S; Cai X; Zhao Y; Li C; Cheng B; Xiong S; Li J; He J; Liang W
    Cancer; 2021 Mar; 127(5):777-786. PubMed ID: 33119182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis.
    Hao W; Zhang J; Wang Y; Fang B; Jin S; Yuan J; Cai W
    Front Immunol; 2023; 14():1175809. PubMed ID: 37520574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies.
    Tang H; Geng R; Xu X; Wang Y; Zhou J; Zhang S; Zhao L; Guan M; Bai C
    Front Immunol; 2022; 13():893179. PubMed ID: 35651612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 37. Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis.
    Song SJ; Song YK; Jang M; Shin E; Suh SY; Cho YS; Lee JY; Oh JM
    Target Oncol; 2023 Jan; 18(1):147-158. PubMed ID: 36515782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thyroid dysfunction induced by anti-PD-1 therapy is associated with a better progression-free survival in patients with advanced carcinoma.
    Lu Y; Li Q; Xu L; Zheng Y; Wang Y; Liu Y; Zhang R; Liao L; Dong J
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16501-16510. PubMed ID: 37715029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.
    Luo W; Wang Z; Tian P; Li W
    J Cancer Res Clin Oncol; 2018 Oct; 144(10):1851-1859. PubMed ID: 30019319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thyroid disorders induced by checkpoint inhibitors.
    Ferrari SM; Fallahi P; Galetta F; Citi E; Benvenga S; Antonelli A
    Rev Endocr Metab Disord; 2018 Dec; 19(4):325-333. PubMed ID: 30242549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.